Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma. (May 2022)

• Record Type: Journal Article
• Authors: Ribeiro, Maurício Fernando Silva Almeida; Gadotti, Luiza Lara; Sacardo, Karina Perez; Lopes, Carlos Diego Holanda; Saddi, Rodrigo; Alessi, João Victor Machado; de Macedo, Mariana Petaccia; do Nascimento, Ellen Caroline Toledo; Testagrossa, Leonardo de Abreu; Katz, Artur
• Is Part Of: SAGE open medical case reports. Volume 10(2022)
• Publication Date: 2022-05
• Subjects: ROS1 proto-oncogene -- non-small cell lung cancer -- crizotinib -- molecular targeted therapy -- case report; Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1177/2050313X221100407
• Languages: English
• ISSNs: 2050-313X

Abstract

Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herein describe a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2 - ROS1 fusion, who had a pronounced and durable response to crizotinib. The present case underscores the importance of pursuing actionable alterations in patients with similar clinical and epidemiological characteristics. In addition, provides the second report of crizotinib activity against lung malignancies harboring the unique SLC12A2-ROS1 fusion and highlights the importance of a deeper understanding of molecular alterations in underrepresented subgroups of patients to tailor the decision-making in daily practice.